Period Invested for | ₹1000 SIP Started on | Investments | Latest Value | Abs. Returns |
---|---|---|---|---|
One Week | 2025-06-06 | ₹1,000.00 | ₹1,017.23 |
1.72 %
|
Two Week | 2025-05-29 | ₹1,000.00 | ₹1,032.46 |
3.25 %
|
One Month | 2025-05-14 | ₹1,000.00 | ₹1,042.88 |
4.29 %
|
Three Months | 2025-03-17 | ₹3,000.00 | ₹3,127.27 |
4.24 %
|
Six Months | 2024-12-16 | ₹6,000.00 | ₹6,194.15 |
3.24 %
|
One Year | 2024-06-13 | ₹12,000.00 | ₹12,270.53 |
2.25 %
|
Three Year | 2022-06-14 | ₹36,000.00 | ₹47,400.73 |
31.67 %
|
Since Inception | 2020-10-26 | ₹57,000.00 | ₹81,494.08 |
42.97 %
|
Company Name | Sector | Sector Type | Nav(in %) |
---|---|---|---|
Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Equity | 12.29 |
Max Healthcare Institute Ltd. | Healthcare Services | Equity | 6.68 |
Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Equity | 6.03 |
Cipla Ltd. | Pharmaceuticals & Biotechnology | Equity | 5.87 |
Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Equity | 5.58 |
Apollo Hospitals Enterprise Ltd. | Healthcare Services | Equity | 5.29 |
Lupin Ltd. | Pharmaceuticals & Biotechnology | Equity | 3.41 |
Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Equity | 2.87 |
Fortis Healthcare Ltd. | Healthcare Services | Equity | 2.65 |
Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Equity | 2.33 |
Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Equity | 2.29 |
Zydus Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Equity | 1.79 |
Laurus Labs Ltd. | Pharmaceuticals & Biotechnology | Equity | 1.63 |
Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Equity | 1.63 |
Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Equity | 1.57 |
IPCA Laboratories Ltd. | Pharmaceuticals & Biotechnology | Equity | 1.52 |
Biocon Ltd. | Pharmaceuticals & Biotechnology | Equity | 1.07 |
GlaxoSmithKline Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Equity | 1.07 |
Narayana Hrudayalaya ltd. | Healthcare Services | Equity | 0.95 |
Piramal Pharma Ltd. | Pharmaceuticals & Biotechnology | Equity | 0.94 |
Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Equity | 0.90 |
Syngene International Ltd. | Healthcare Services | Equity | 0.89 |
Ajanta Pharma Ltd. | Pharmaceuticals & Biotechnology | Equity | 0.84 |
Cohance Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Equity | 0.81 |
Global Health Ltd. | Healthcare Services | Equity | 0.73 |
ELI LILLY & CO | Pharmaceuticals | Debt | 4.86 |
JOHNSON & JOHNSON | Pharmaceuticals | Debt | 3.05 |
ABBVIE INC | Biotechnology | Debt | 2.68 |
Novo Nordisk A/S | Pharmaceuticals & Biotechnology | Debt | 1.88 |
ABBOTT LABORATORIES | Health Care Equipment & Supplies | Debt | 1.87 |
NOVARTIS AG | Pharmaceuticals | Debt | 1.86 |
INTUITIVE SURGICAL INC | Health Care Equipment & Supplies | Debt | 1.61 |
MERCK & CO.INC | Pharmaceuticals | Debt | 1.59 |
AMGEN INC | Biotechnology | Debt | 1.26 |
THERMO FISHER SCIENTIFIC INC | Life Sciences Tools & Services | Debt | 1.26 |
GILEAD SCIENCES INC | Biotechnology | Debt | 1.10 |
STRYKER CORP | Health Care Equipment & Supplies | Debt | 1.07 |
DANAHER CORP | Health Care Equipment & Supplies | Debt | 1.01 |
VERTEX PHARMACEUTICALS INC | Biotechnology | Debt | 0.93 |
MEDTRONIC PLC | Health Care Equipment & Supplies | Debt | 0.87 |
Regeneron Pharmaceuticals Inc | Pharmaceuticals | Debt | 0.43 |
BECTON DICKINSON AND CO | Health Care Equipment & Supplies | Debt | 0.41 |
AGILENT TECHNOLOGIES INC | Life Sciences Tools & Services | Debt | 0.26 |
IQVIA HOLDINGS INC | Life Sciences Tools & Services | Debt | 0.21 |
ILLUMINA INC | Life Sciences Tools & Services | Debt | 0.11 |
Clearing Corporation of India Ltd. | - | Debt | 0.12 |
Net Receivables/(Payables) | - | - | -0.07 |
India's "lock-in period" in mutual funds encourages long-term investment, particularly in tax-saving schemes preventing redemption or selling of units.
Lock-in times for various investment types
Residual maturity is the remaining time until a security reaches its maturity date. It is an important factor for investors to consider when evaluating the risk associated with an investment.
There are two different types of residual maturity.
Scheme Name | 1Y Return | 3Y Return | SI Return |
---|---|---|---|
HDFC Nifty 100 ETF |
9.88%
|
5.38%
|
9.06%
|
LIC MF Nifty Midcap 100 ETF - GROWTH |
9.84%
|
8.76%
|
14.28%
|
Baroda BNP Paribas NIFTY Bank ETF - Regular Plan - Growth |
9.82%
|
4.80%
|
10.75%
|
KOTAK NIFTY SDL PLUS AAA PSU BOND JUL 2028 60:40 INDEX FUND - Regular Plan - Growth |
9.79%
|
11.04%
|
8.27%
|
DSP NiftySDLPlus G-SecJun2028 30:70IndexFund -Regular Plan - Growth Mat.Dt.30-06-2028 |
9.75%
|
12.42%
|
6.99%
|
BARODA BNP PARIBAS BANKING AND PSU BOND FUND - REGULAR PLAN - GROWTH |
9.70%
|
11.06%
|
5.46%
|
DSP Nifty 50 Equal Weight ETF |
9.58%
|
33.13%
|
14.03%
|
Kotak Nifty Commodities Index Fund Regular Plan - Growth |
9.54%
|
4.66%
|
60.82%
|
ICICI Prudential Nifty SDL Sep 2027 Index Fund - Growth |
9.49%
|
12.24%
|
6.70%
|
Tata Nifty SDL Plus AAA PSU Bond Dec 2027 60: 40 Index Fund - Regular Plan - Growth |
9.46%
|
12.02%
|
6.95%
|
Scheme Name | 1Y Return | 3Y Return | SI Return |
---|---|---|---|
Edelweiss Banking and PSU Debt Fund - Regular Plan - Growth |
9.89%
|
12.31%
|
8.03%
|
Edelweiss Tax Advantage Fund - Regular Plan - Growth |
9.74%
|
11.24%
|
13.46%
|
Edelweiss Fixed Maturity Plan - Series 32 - Regular Plan - Growth |
9.54%
|
4.66%
|
9.54%
|
Edelweiss Flexi Cap Fund - Regular Plan - Growth |
9.48%
|
35.40%
|
13.62%
|
Edelweiss CRISIL IBX 50:50 Gilt Plus SDL Short Duration Index Fund - Regular Plan - Growth |
9.36%
|
9.36%
|
8.26%
|
Edelweiss ELSS Tax saver Fund - Regular Plan - Growth |
9.20%
|
30.76%
|
15.61%
|
Edelweiss Multi Asset Allocation Fund - Regular Plan - Growth |
8.96%
|
7.76%
|
8.17%
|
Edelweiss Income Fund - Series 301 - Growth |
8.55%
|
12.92%
|
8.43%
|
Edelweiss NIFTY Large Mid Cap 250 Index Fund - Regular Plan - Growth |
8.30%
|
34.34%
|
14.97%
|
Edelweiss Large Cap Fund - Plan C Growth |
8.28%
|
30.51%
|
14.12%
|
Interested in exploring more about JezzMoney Mutual Fund Distributors Software? Submit the form, and we will respond quickly.